Literature DB >> 911218

Naltrexone and cyclazocine. A controlled treatment study.

L S Brahen, T Capone, V Wiechert, D Desiderio.   

Abstract

The induction side effects of cyclazocine and naltrexone were compared in double-blind placebo-controlled studies involving 40 patients (20 for each drug). These studies were carried out with a twice-a-day dosage regimen. Naltrexone produced fewer side effects than cyclazocine. Naltrexone side effects fell to levels indistinguishable from those of placebo in the "induction after placebo" phase. In contrast, cyclazocine "induction after placebo" produced an even higher level of side effects than found in its induction. In no case was naltrexone discontinued because of side effects. On the other hand, three of 20 cyclazocine-treated patients discontinued the drug because of distressing side effects. No toxicity was noted with either agent. The controlled data reported supports the clinical impression that naltrexone produces fewer induction side effects than cyclazocine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911218     DOI: 10.1001/archpsyc.1977.01770220063007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  5 in total

Review 1.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

3.  The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.

Authors:  Jermaine D Jones; Mudassir Mumtaz; Nehal P Vadhan; Suky Martinez; Satadru Pramanik; Jeanne Manubay; Shanthi Mogali; Freymon Perez; Felipe Castillo; Henry R Kranzler; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2022-04-12       Impact factor: 2.277

4.  Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs.

Authors:  M A Hussain; E Shefter
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

Review 5.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.